Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.50 |
| ▸ | HPGD | P15428 | 4/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.42 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28010768 | 0.82 | TSHR (0.58) | KDM4EALDH1A1HPGDHSD17B10KMT2A | |
| SCHEMBL1127360 | 0.81 | KMT2A (0.65) | KDM4EALDH1A1HPGDHSD17B10SIRT2 | |
| SCHEMBL3458186 | 0.79 | KDM4E (0.55) | KDM4EALDH1A1HPGDHSD17B10SIRT2 | |
| SCHEMBL10636097 | 0.79 | KDM4E (0.55) | KDM4EALDH1A1HPGDHSD17B10SIRT2 | |
| SCHEMBL22638691 | 0.78 | KDM4E (0.62) | KDM4EALDH1A1HPGDHSD17B10SIRT2 | |
| Benzene SCHEMBL28257697 | 0.77 | KDM4E (0.54) | KDM4EALDH1A1HPGDHSD17B10SIRT2 | |
| SCHEMBL2562500 | 0.76 | BCAT2 (0.53) | IRAK4 | |
| SCHEMBL10878737 | 0.75 | NR3C1 (0.46) | KDM4EALDH1A1HPGDHSD17B10KMT2A | |
| SCHEMBL2104582 | 0.75 | KDM4E (0.50) | KDM4EALDH1A1HPGDHSD17B10SIRT2 | |
| SCHEMBL30547565 | 0.75 | KDM1A (0.47) | ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240074995-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2024-03-07 | — | — | US | disclosed |
| US-11793777-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FIRST WAVE BIO, INC. (US) | 2023-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240074995-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | KDM4E 2452/4885ALDH1A1 2174/4885HPGD 101/4885 |
| US-11793777-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FH, CS, ECHS1 | KDM4E 2466/4885ALDH1A1 2230/4885HPGD 92/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.